Abstract 4378: BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS-mutant preclinical models
2025; American Association for Cancer Research; Volume: 85; Issue: 8_Supplement_1 Linguagem: Inglês
10.1158/1538-7445.am2025-4378
ISSN1538-7445
AutoresCristóbal Espinosa‐Ruíz, Kanchan Singh, Zuhui Zhang, Kyle A. Sullivan, Nadege Gitego, Megan Rigby, Roger Ma, Patrick Alexander, Saman Setoodeh, Shu Jin, Kenneth Lin, Dana Rabara, Erik K. Larsen, Alok K. Sharma, Albert H. Chan, Bryan D. Smith, Andrew Stephen, Yue Yang, Jun Pei, Felice C. Lightstone, Dhirendra K. Simanshu, Rui Xu, Chunmei Ji, Keshi Wang, Bin Wang, Kerstin W. Sinkevicius, Dwight V. Nissley, Eli Wallace, Frank McCormick, Anna Maciąg, Pedro J. Beltran,
Tópico(s)Cancer Treatment and Pharmacology
Referência(s)